This site is intended for healthcare professionals

Apellis and Sobi announce EU approval of Aspaveli for treatment of paroxysmal nocturnal hemoglobinuria.

Read time: 1 mins
Published:16th Dec 2021
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Sobi) announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan), the first and only targeted C3 therapy, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who are anemic after treatment with a C5 inhibitor for at least three months.

Based on the recommendation from the European Medicines Agency’s Committee for Orphan Medicinal Products, the EC determined that pegcetacoplan continues to meet the criteria for the orphan drug designation status granted in 2017 for the treatment of PNH.

The approval is based on the results from the head-to-head PEGASUS Phase III study, which evaluated the efficacy and safety of Aspaveli compared to eculizumab at 16 weeks in adults with PNH who had persistent anaemia despite treatment with eculizumab. The full safety and efficacy results were published in The New England Journal of Medicine in March 2021.

Condition: Paroxysmal Nocturnal Haemoglobinuria
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.